Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.76
-0.28 (-3.98%)
At close: Sep 12, 2025, 4:00 PM EDT
6.93
+0.17 (2.56%)
After-hours: Sep 12, 2025, 7:22 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
219.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 2.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SGMT News
- 3 days ago - Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - GlobeNewsWire
- 5 days ago - Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 14 days ago - Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development - Seeking Alpha
- 18 days ago - Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 weeks ago - Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 3 months ago - Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewsWire
- 3 months ago - Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 - Seeking Alpha